Jazz Pharmaceuticals plc (JAZZ) has announced the pricing of $850 million in aggregate principal amount of 3.125% exchangeable senior notes, due 2030, in a private offering orchestrated by Jazz Investments I Limited, a wholly-owned subsidiary. The notes are being offered exclusively to qualified institutional buyers, and the issuer has extended an option to the initial purchasers to acquire up to an additional $150 million in aggregate principal amount. The transaction is anticipated to be finalized by September 6, 2024.
The issuer forecasts net proceeds from the offering to be approximately $833.7 million. Jazz Pharmaceuticals, in conjunction with its consolidated subsidiaries, plans to allocate a portion of these proceeds, up to approximately $350 million, to prepay existing term loans under the current credit agreement. The remaining funds will be used for general corporate purposes.
